CD4 and neoplasm: We found that CD4-depleted mice treated with CRTE6E7L2 DNA vaccine had a significantly greater percentage of E7-specific CD8+ T cells among total CD8+ T cells compared to naïve or untreated tumor-bearing mice (Figure 5B).